266 related articles for article (PubMed ID: 20142330)
21. Loss of LKB1 in high-grade endometrial carcinoma: LKB1 is a novel transcriptional target of p53.
Co NN; Iglesias D; Celestino J; Kwan SY; Mok SC; Schmandt R; Lu KH
Cancer; 2014 Nov; 120(22):3457-68. PubMed ID: 25042259
[TBL] [Abstract][Full Text] [Related]
22. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
[TBL] [Abstract][Full Text] [Related]
23. Effect of mTOR inhibitors in nude mice with endometrial carcinoma and variable PTEN expression status.
Fong P; Meng LR
Med Sci Monit Basic Res; 2014 Sep; 20():146-52. PubMed ID: 25266877
[TBL] [Abstract][Full Text] [Related]
24. Cells expressing PAX8 are the main source of homeostatic regeneration of adult mouse endometrial epithelium and give rise to serous endometrial carcinoma.
Fu DJ; De Micheli AJ; Bidarimath M; Ellenson LH; Cosgrove BD; Flesken-Nikitin A; Nikitin AY
Dis Model Mech; 2020 Oct; 13(10):. PubMed ID: 32998907
[TBL] [Abstract][Full Text] [Related]
25. Loss of LKB1 expression reduces the latency of ErbB2-mediated mammary gland tumorigenesis, promoting changes in metabolic pathways.
Andrade-Vieira R; Xu Z; Colp P; Marignani PA
PLoS One; 2013; 8(2):e56567. PubMed ID: 23451056
[TBL] [Abstract][Full Text] [Related]
26. Dissecting the role of mTOR: lessons from mTOR inhibitors.
Dowling RJ; Topisirovic I; Fonseca BD; Sonenberg N
Biochim Biophys Acta; 2010 Mar; 1804(3):433-9. PubMed ID: 20005306
[TBL] [Abstract][Full Text] [Related]
27. Conditional abrogation of transforming growth factor-β receptor 1 in PTEN-inactivated endometrium promotes endometrial cancer progression in mice.
Gao Y; Lin P; Lydon JP; Li Q
J Pathol; 2017 Sep; 243(1):89-99. PubMed ID: 28657664
[TBL] [Abstract][Full Text] [Related]
28. Co-targeting PLK1 and mTOR induces synergistic inhibitory effects against esophageal squamous cell carcinoma.
Liu TT; Yang KX; Yu J; Cao YY; Ren JS; Hao JJ; Pan BQ; Ma S; Yang LY; Cai Y; Wang MR; Zhang Y
J Mol Med (Berl); 2018 Aug; 96(8):807-817. PubMed ID: 29959473
[TBL] [Abstract][Full Text] [Related]
29. LKB1 as a Tumor Suppressor in Uterine Cancer: Mouse Models and Translational Studies.
Peña CG; Castrillón DH
Adv Exp Med Biol; 2017; 943():211-241. PubMed ID: 27910069
[TBL] [Abstract][Full Text] [Related]
30. Targeting adhesion signaling in
Gilbert-Ross M; Konen J; Koo J; Shupe J; Robinson BS; Wiles WG; Huang C; Martin WD; Behera M; Smith GH; Hill CE; Rossi MR; Sica GL; Rupji M; Chen Z; Kowalski J; Kasinski AL; Ramalingam SS; Fu H; Khuri FR; Zhou W; Marcus AI
JCI Insight; 2017 Mar; 2(5):e90487. PubMed ID: 28289710
[TBL] [Abstract][Full Text] [Related]
31. Rapamycin enhances growth inhibition on urothelial carcinoma cells through LKB1 deficiency-mediated mitochondrial dysregulation.
Whang YM; Kim MJ; Cho MJ; Yoon H; Choi YW; Kim TH; Chang IH
J Cell Physiol; 2019 Aug; 234(8):13083-13096. PubMed ID: 30549029
[TBL] [Abstract][Full Text] [Related]
32. The tumor suppressor kinase LKB1: lessons from mouse models.
Ollila S; Mäkelä TP
J Mol Cell Biol; 2011 Dec; 3(6):330-40. PubMed ID: 21926085
[TBL] [Abstract][Full Text] [Related]
33. Antitumor activity of a combination of dual PI3K/mTOR inhibitor SAR245409 and selective MEK1/2 inhibitor pimasertib in endometrial carcinomas.
Inaba K; Oda K; Ikeda Y; Sone K; Miyasaka A; Kashiyama T; Fukuda T; Uehara Y; Arimoto T; Kuramoto H; Wada-Hiraike O; Kawana K; Yano T; Osuga Y; Fujii T
Gynecol Oncol; 2015 Aug; 138(2):323-31. PubMed ID: 26033306
[TBL] [Abstract][Full Text] [Related]
34. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
[TBL] [Abstract][Full Text] [Related]
35. Targeting LKB1 signaling in cancer.
Korsse SE; Peppelenbosch MP; van Veelen W
Biochim Biophys Acta; 2013 Apr; 1835(2):194-210. PubMed ID: 23287572
[TBL] [Abstract][Full Text] [Related]
36. Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer.
Seager CM; Puzio-Kuter AM; Patel T; Jain S; Cordon-Cardo C; Mc Kiernan J; Abate-Shen C
Cancer Prev Res (Phila); 2009 Dec; 2(12):1008-14. PubMed ID: 19952358
[TBL] [Abstract][Full Text] [Related]
37. LKB1 deletion with the RIP2.Cre transgene modifies pancreatic beta-cell morphology and enhances insulin secretion in vivo.
Sun G; Tarasov AI; McGinty JA; French PM; McDonald A; Leclerc I; Rutter GA
Am J Physiol Endocrinol Metab; 2010 Jun; 298(6):E1261-73. PubMed ID: 20354156
[TBL] [Abstract][Full Text] [Related]
38. Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction.
Ikeda Y; Sato K; Pimentel DR; Sam F; Shaw RJ; Dyck JR; Walsh K
J Biol Chem; 2009 Dec; 284(51):35839-49. PubMed ID: 19828446
[TBL] [Abstract][Full Text] [Related]
39. The effect of mTOR inhibition alone or combined with MEK inhibitors on brain metastasis: an in vivo analysis in triple-negative breast cancer models.
Zhao H; Cui K; Nie F; Wang L; Brandl MB; Jin G; Li F; Mao Y; Xue Z; Rodriguez A; Chang J; Wong ST
Breast Cancer Res Treat; 2012 Jan; 131(2):425-36. PubMed ID: 21394501
[TBL] [Abstract][Full Text] [Related]
40. The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines.
Ma BB; Lui VW; Hui EP; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Chan AT
Invest New Drugs; 2010 Aug; 28(4):413-20. PubMed ID: 19471857
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
